董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh Muntner | 男 | Director | 57 | 未披露 | 1.00 | 2026-07-27 |
| Kira Sheinerman | 女 | Director | 56 | 未披露 | 1.00 | 2026-07-27 |
| André P. Boulet | 男 | Chairman and Chief Executive Officer and Director | 68 | 51.16万 | 38.60 | 2026-07-27 |
| Pierre Labbé | 男 | Director | 60 | 未披露 | 0.61 | 2026-07-27 |
| Kathryn Gregory | 女 | Director | 63 | 未披露 | 1.20 | 2026-07-27 |
| Luc Grégoire | 男 | Director and Executive Vice President Strategy | 66 | 15.22万 | 11.72 | 2026-07-27 |
| Louis Flamand | 男 | Director | 59 | 0.40万 | 1.76 | 2026-07-27 |
| Luc Buisson | 男 | Director | 63 | 未披露 | 1.00 | 2026-07-27 |
| Dennis Turpin | 男 | Chief Financial Officer and Director | 63 | 24.10万 | 3.84 | 2026-07-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| André P. Boulet | 男 | Chairman and Chief Executive Officer and Director | 68 | 51.16万 | 38.60 | 2026-07-27 |
| Luc Grégoire | 男 | Director and Executive Vice President Strategy | 66 | 15.22万 | 11.72 | 2026-07-27 |
| Dennis Turpin | 男 | Chief Financial Officer and Director | 63 | 24.10万 | 3.84 | 2026-07-27 |
董事简历
中英对照 | 中文 | 英文- Josh Muntner
-
Josh Muntner，2015年起担任业务发展高级副总裁。他有着超过15年的辅助生命科学融资和并购咨询交易公司经验。此前，2012-2015，他在金融服务公司-Janney Montgomery Scott担任总经理和医疗投资银行业务联合主管。2009-2012年，他在投资银行-ThinkEquity担任总经理。此前，他在Oppenheimer & Co.及其美国前身-CIBC World Markets工作9年，担任重要职位。他还曾在Prudential Securities担任投资银行家。他持有Carnegie Mellon的B.F.A。学位，以及UCLA大学Anderson 学院的工商管理硕士学位。
Josh Muntner has served as the Senior Vice President of Business Development since 2015 and as a member of the Interim Office of the Chief Executive Officer since March 2017. Prior to joining ContraFect, he served as Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, a financial services firm from 2012 to 2015. Mr. Muntner was also a Managing Director at ThinkEquity, an investment bank from 2009 to 2012. Previously, Mr. Muntner spent nine years at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, in positions of increasing responsibility. Mr. Muntner also served as an investment banker at Prudential Securities. Mr. Muntner received his B.F.A. degree from Carnegie Mellon and his M.B.A. degree from The Anderson School at UCLA. - Josh Muntner，2015年起担任业务发展高级副总裁。他有着超过15年的辅助生命科学融资和并购咨询交易公司经验。此前，2012-2015，他在金融服务公司-Janney Montgomery Scott担任总经理和医疗投资银行业务联合主管。2009-2012年，他在投资银行-ThinkEquity担任总经理。此前，他在Oppenheimer & Co.及其美国前身-CIBC World Markets工作9年，担任重要职位。他还曾在Prudential Securities担任投资银行家。他持有Carnegie Mellon的B.F.A。学位，以及UCLA大学Anderson 学院的工商管理硕士学位。
- Josh Muntner has served as the Senior Vice President of Business Development since 2015 and as a member of the Interim Office of the Chief Executive Officer since March 2017. Prior to joining ContraFect, he served as Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, a financial services firm from 2012 to 2015. Mr. Muntner was also a Managing Director at ThinkEquity, an investment bank from 2009 to 2012. Previously, Mr. Muntner spent nine years at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, in positions of increasing responsibility. Mr. Muntner also served as an investment banker at Prudential Securities. Mr. Muntner received his B.F.A. degree from Carnegie Mellon and his M.B.A. degree from The Anderson School at UCLA.
- Kira Sheinerman
-
Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY. - Kira Sheinerman于2009年9月加入DiamiR，是DiamiR的联合创始人和执行董事。谢纳曼博士还是DiamiR，LLC在股份交换前后的执行主席。自2015年11月起，Sheinerman博士担任H.C. Wainwright & Co.，LLC医疗保健投资银行业务董事总经理，负责成长型生命科学公司的财务和战略交易。此前，她曾于2012年至2013年在Burrill & Company担任医疗投资银行业务董事总经理，并于2005年至2012年在Rodman & Renshaw担任董事总经理。在投资银行业务之前，谢纳曼博士曾在生命科学战略咨询公司Arcus集团工作。2010年至2021年，她担任康奈尔大学附属机构Boyce Thompson研究所的董事会成员；2015年至2018年，她担任阿尔茨海默氏症协会商业联盟的联合主席；2020年至2023年，她担任知临集团（纳斯达克股票代码：APM）的高级战略顾问。2008年至2009年，SheNerman博士担任Xenomics（现为Cardiff Oncology；NASDAQ：CRDF）董事会执行委员会主席。谢纳曼博士因其在阿尔茨海默病分子机制方面的工作而获得西奈山医学院生物医学科学博士学位。谢纳曼博士还拥有巴鲁克学院/纽约市立大学Zicklin商学院的荣誉MBA学位。
- Kira Sheinerman joined DiamiR in September 2009, and is DiamiR's Co Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously, she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm. From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015 through 2018 she served as the co chair of Alzheimer's Association Business Consortium; and from 2020 to 2023 she served as the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008 2009, Dr. Sheinerman chaired the Board Executive Committee of Xenomics (now Cardiff Oncology; NASDAQ: CRDF). Dr. Sheinerman received her Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine for her work on molecular mechanisms of Alzheimer's Disease. Dr. Sheinerman also holds an Honors MBA from the Zicklin School of Business, Baruch College/CUNY.
- André P. Boulet
-
Andr é P. Boulet在制药和生物技术领域的药物开发、监管事务、市场准入、融资和重组方面拥有丰富的经验。2025年6月，他被任命为首席执行官兼首席科学官（“CSO”）。2022年8月，Boulet博士被任命为公司CSO。2015年3月至2022年8月，Boulet博士担任公司总裁兼首席执行官，并购买了PurGenesis Technologies Inc.（“PurGenesis”）的资产，该公司是一家专门开发植物药物以及皮肤美容产品的公司。此外，他在2013年7月至2015年2月期间担任顾问。他与美国一家大型有机农场建立了战略合作伙伴关系，以供应用于提取PurGenesis旗舰产品的原材料。在他的领导下，还建造了一座药物提取设施。在加入PurGenesis之前，Boulet博士是SIPAR BIO Inc.的合伙人兼科学事务副总裁，该公司是一家私募股权团队，也是加拿大生物技术公司BioCapital Investment Limited Partnership和BioCapital Mutual Fund（19962002）的合伙人，负责投资战略、交易发展分析、估值以及对私营和上市公司的选定投资的谈判。Boulet博士还在2000年11月至2008年12月期间担任Bioxel Pharma Inc.的董事和高级管理人员。在其整个职业生涯中，Boulet博士与Hoechst Marion Roussel Inc.、Marion Merrell Dow Canada Inc.和Nordic Laboratories Inc.（现为赛诺菲 Canada Inc.）合作，发展了药物开发和健康经济学方面的国际专业知识。Boulet博士自1981年9月起拥有魁北克河畔三河大学医学生物学学士学位，并于1985年6月获得实验医学/免疫学免疫化学硕士学位，于1988年6月获得魁北克市拉瓦尔大学生理内分泌学博士学位。他还在美国宾夕法尼亚大学完成了生物化学和生物物理学博士后研究金，并在英国约克大学完成了卫生经济学培训项目。他因基础研究连续两年获得Ortho Pharmaceutical奖，分别于1986年和1987年；获得Fonds de Recherche du Qu é bec — Sant é的研究生奖学金（19871988）和博士后培训（19881990）。他于1993年成为美国高血压学会的教员，并于1994年至1996年在FDA心肺CRADA指导委员会任职，评估动态血压监测数据在批准新型抗高血压药物方面的潜在用途。他是多篇与基础和临床研究、金融和卫生经济学相关的手稿的作者或合著者。他是三项专利的共同作者。
André P. Boulet has vast experience in drug development, regulatory affairs, market access, financing and restructuring in the pharmaceutical and biotech fields. In June 2025, he was appointed as CEO and Chief Scientific Officer ("CSO"). In August 2022, Dr. Boulet was appointed as CSO of the Company. From March 2015 to August 2022, Dr. Boulet was President and CEO of the Company and purchased the assets of PurGenesis Technologies Inc., ("PurGenesis") a corporation specialized in the development of botanical drugs as well as derma cosmetic products. Also, he was a consultant from July 2013 to February 2015. He established a strategic partnership with a large United States based organic farm to supply the raw material used for the extraction of PurGenesis' flagship product. A pharmaceutical extraction facility was also built under his leadership. Prior to joining PurGenesis, Dr. Boulet was partner and Vice President Scientific affairs of SIPAR BIO Inc., a private equity team and a partner in BioCapital Investment Limited Partnership and BioCapital Mutual Fund (1996 2002), a Canadian biotechnology corporation, where he was responsible for investment strategy, deal development analysis, valuation, and negotiation of selected investments in private and publicly traded corporations. Dr. Boulet has also been a Director and Senior Officer of Bioxel Pharma Inc. from November 2000 to December 2008. Throughout his career, Dr. Boulet developed international expertise in the drug development and health economics, working with Hoechst Marion Roussel Inc., Marion Merrell Dow Canada Inc. and Nordic Laboratories Inc. (now Sanofi Canada Inc.). Dr. Boulet holds a bachelor's degree in medical biology from Université du Québec à Trois Rivières since September 1981, a master's degree in experimental medicine/immunology immunochemistry as well in June 1985 and a Ph.D. in physiology endocrinology in June 1988 from Université Laval in Québec City. He also completed a postdoctoral fellowship in biochemistry and biophysics at the University of Pennsylvania, in the United States, and a training program in health economics at York University, in the United Kingdom. He received the Ortho Pharmaceutical award for basic research, on two consecutive years, in 1986 and 1987; received Graduate Student Fellowship (1987 1988) and Postdoctoral training (1988 1990) both from the Fonds de Recherche du Québec—Santé. He was Faculty member of the American Society of Hypertension, Inc. in 1993 and served on the FDA Cardio Renal CRADA Steering Committee from 1994 to 1996, assessing the potential use of ambulatory blood pressure monitoring data for the approval of new anti hypertensive drugs. He is the author or co author of many manuscripts related to basic and clinical research, finance and health economics. He is the co author of three patents. - Andr é P. Boulet在制药和生物技术领域的药物开发、监管事务、市场准入、融资和重组方面拥有丰富的经验。2025年6月，他被任命为首席执行官兼首席科学官（“CSO”）。2022年8月，Boulet博士被任命为公司CSO。2015年3月至2022年8月，Boulet博士担任公司总裁兼首席执行官，并购买了PurGenesis Technologies Inc.（“PurGenesis”）的资产，该公司是一家专门开发植物药物以及皮肤美容产品的公司。此外，他在2013年7月至2015年2月期间担任顾问。他与美国一家大型有机农场建立了战略合作伙伴关系，以供应用于提取PurGenesis旗舰产品的原材料。在他的领导下，还建造了一座药物提取设施。在加入PurGenesis之前，Boulet博士是SIPAR BIO Inc.的合伙人兼科学事务副总裁，该公司是一家私募股权团队，也是加拿大生物技术公司BioCapital Investment Limited Partnership和BioCapital Mutual Fund（19962002）的合伙人，负责投资战略、交易发展分析、估值以及对私营和上市公司的选定投资的谈判。Boulet博士还在2000年11月至2008年12月期间担任Bioxel Pharma Inc.的董事和高级管理人员。在其整个职业生涯中，Boulet博士与Hoechst Marion Roussel Inc.、Marion Merrell Dow Canada Inc.和Nordic Laboratories Inc.（现为赛诺菲 Canada Inc.）合作，发展了药物开发和健康经济学方面的国际专业知识。Boulet博士自1981年9月起拥有魁北克河畔三河大学医学生物学学士学位，并于1985年6月获得实验医学/免疫学免疫化学硕士学位，于1988年6月获得魁北克市拉瓦尔大学生理内分泌学博士学位。他还在美国宾夕法尼亚大学完成了生物化学和生物物理学博士后研究金，并在英国约克大学完成了卫生经济学培训项目。他因基础研究连续两年获得Ortho Pharmaceutical奖，分别于1986年和1987年；获得Fonds de Recherche du Qu é bec — Sant é的研究生奖学金（19871988）和博士后培训（19881990）。他于1993年成为美国高血压学会的教员，并于1994年至1996年在FDA心肺CRADA指导委员会任职，评估动态血压监测数据在批准新型抗高血压药物方面的潜在用途。他是多篇与基础和临床研究、金融和卫生经济学相关的手稿的作者或合著者。他是三项专利的共同作者。
- André P. Boulet has vast experience in drug development, regulatory affairs, market access, financing and restructuring in the pharmaceutical and biotech fields. In June 2025, he was appointed as CEO and Chief Scientific Officer ("CSO"). In August 2022, Dr. Boulet was appointed as CSO of the Company. From March 2015 to August 2022, Dr. Boulet was President and CEO of the Company and purchased the assets of PurGenesis Technologies Inc., ("PurGenesis") a corporation specialized in the development of botanical drugs as well as derma cosmetic products. Also, he was a consultant from July 2013 to February 2015. He established a strategic partnership with a large United States based organic farm to supply the raw material used for the extraction of PurGenesis' flagship product. A pharmaceutical extraction facility was also built under his leadership. Prior to joining PurGenesis, Dr. Boulet was partner and Vice President Scientific affairs of SIPAR BIO Inc., a private equity team and a partner in BioCapital Investment Limited Partnership and BioCapital Mutual Fund (1996 2002), a Canadian biotechnology corporation, where he was responsible for investment strategy, deal development analysis, valuation, and negotiation of selected investments in private and publicly traded corporations. Dr. Boulet has also been a Director and Senior Officer of Bioxel Pharma Inc. from November 2000 to December 2008. Throughout his career, Dr. Boulet developed international expertise in the drug development and health economics, working with Hoechst Marion Roussel Inc., Marion Merrell Dow Canada Inc. and Nordic Laboratories Inc. (now Sanofi Canada Inc.). Dr. Boulet holds a bachelor's degree in medical biology from Université du Québec à Trois Rivières since September 1981, a master's degree in experimental medicine/immunology immunochemistry as well in June 1985 and a Ph.D. in physiology endocrinology in June 1988 from Université Laval in Québec City. He also completed a postdoctoral fellowship in biochemistry and biophysics at the University of Pennsylvania, in the United States, and a training program in health economics at York University, in the United Kingdom. He received the Ortho Pharmaceutical award for basic research, on two consecutive years, in 1986 and 1987; received Graduate Student Fellowship (1987 1988) and Postdoctoral training (1988 1990) both from the Fonds de Recherche du Québec—Santé. He was Faculty member of the American Society of Hypertension, Inc. in 1993 and served on the FDA Cardio Renal CRADA Steering Committee from 1994 to 1996, assessing the potential use of ambulatory blood pressure monitoring data for the approval of new anti hypertensive drugs. He is the author or co author of many manuscripts related to basic and clinical research, finance and health economics. He is the co author of three patents.
- Pierre Labbé
-
Pierre Labb é在各个行业拥有超过30年的渐进式财务领导经验。他目前担任Fonds QScale S.E.C.的财务执行副总裁，该公司是一家为大规模训练和推理而设计的组织建设和运营高密度AI托管设施。在这个职位上，他负责监督财务战略、投资者关系、财务报告、税务、财务和风险管理。在加入Fonds QScale S.E.C.之前，Labb é先生曾在IMV公司担任五年的首席财务官（“CFO”）。他此前还曾在LeddarTech Inc.和Medicago Inc.（“TSX”）担任首席财务官和公司秘书职务。此外，Labb é先生自2015年起担任Osisko Gold Royalties Ltd的董事，该公司是一家在多伦多证券交易所和纽约证券交易所上市的贵金属特许权使用费公司。他目前担任人力资源委员会主席以及审计和风险委员会成员。作为一名高级财务主管，拉贝先生在融资、合并和收购方面发挥了关键作用，监督总额超过10亿美元的交易。Labb é先生拥有魁北克市拉瓦尔大学工商管理学士学位和会计学执照。他是加拿大特许专业会计师协会、魁北克特许专业会计师协会和公司董事协会的成员，在那里他还获得了ICD.D的称号。
Pierre Labbé has over 30 years of progressive financial leadership experience across various industries. He is currently the Executive Vice President, Finance at Fonds QScale S.E.C., an organization building and operating high density AI colocation facilities designed for large scale training and inference. In this role, he oversees financial strategy, investor relations, financial reporting, tax, treasury, and risk management. Prior to joining Fonds QScale S.E.C., Mr. Labbé served for five years as Chief Financial Officer ("CFO") of IMV Inc. He also previously held the positions of CFO and Corporate Secretary at LeddarTech Inc. and Medicago Inc. ("TSX"). In addition, Mr. Labbé has been a Director of Osisko Gold Royalties Ltd., a TSX and NYSE listed precious metal royalty company, since 2015. He currently serves as Chair of the Human Resources Committee and as a member of the Audit and Risk Committee. As a senior financial executive, Mr. Labbé has played a key role in financing, mergers, and acquisitions, overseeing transactions totaling over $1 billion. Mr. Labbé holds a Bachelor's Degree in Business Administration and a license in accounting from Université Laval in Quebec City. He is a member of the Chartered Professional Accountants of Canada, the Québec Chartered Professional Accountants Order, and the Institute of Corporate Directors, where he also earned the ICD.D designation. - Pierre Labb é在各个行业拥有超过30年的渐进式财务领导经验。他目前担任Fonds QScale S.E.C.的财务执行副总裁，该公司是一家为大规模训练和推理而设计的组织建设和运营高密度AI托管设施。在这个职位上，他负责监督财务战略、投资者关系、财务报告、税务、财务和风险管理。在加入Fonds QScale S.E.C.之前，Labb é先生曾在IMV公司担任五年的首席财务官（“CFO”）。他此前还曾在LeddarTech Inc.和Medicago Inc.（“TSX”）担任首席财务官和公司秘书职务。此外，Labb é先生自2015年起担任Osisko Gold Royalties Ltd的董事，该公司是一家在多伦多证券交易所和纽约证券交易所上市的贵金属特许权使用费公司。他目前担任人力资源委员会主席以及审计和风险委员会成员。作为一名高级财务主管，拉贝先生在融资、合并和收购方面发挥了关键作用，监督总额超过10亿美元的交易。Labb é先生拥有魁北克市拉瓦尔大学工商管理学士学位和会计学执照。他是加拿大特许专业会计师协会、魁北克特许专业会计师协会和公司董事协会的成员，在那里他还获得了ICD.D的称号。
- Pierre Labbé has over 30 years of progressive financial leadership experience across various industries. He is currently the Executive Vice President, Finance at Fonds QScale S.E.C., an organization building and operating high density AI colocation facilities designed for large scale training and inference. In this role, he oversees financial strategy, investor relations, financial reporting, tax, treasury, and risk management. Prior to joining Fonds QScale S.E.C., Mr. Labbé served for five years as Chief Financial Officer ("CFO") of IMV Inc. He also previously held the positions of CFO and Corporate Secretary at LeddarTech Inc. and Medicago Inc. ("TSX"). In addition, Mr. Labbé has been a Director of Osisko Gold Royalties Ltd., a TSX and NYSE listed precious metal royalty company, since 2015. He currently serves as Chair of the Human Resources Committee and as a member of the Audit and Risk Committee. As a senior financial executive, Mr. Labbé has played a key role in financing, mergers, and acquisitions, overseeing transactions totaling over $1 billion. Mr. Labbé holds a Bachelor's Degree in Business Administration and a license in accounting from Université Laval in Quebec City. He is a member of the Chartered Professional Accountants of Canada, the Québec Chartered Professional Accountants Order, and the Institute of Corporate Directors, where he also earned the ICD.D designation.
- Kathryn Gregory
-
Kathryn Gregory在初创、中型和大型制药和生物技术公司拥有超过25年的执行领导经验。她在国际业务发展方面拥有丰富的经验，包括公司战略、许可、并购和联盟管理。Gregory女士于2024年2月加入公司董事会，并担任人力资源委员会主席。她也是美容公司Carmell Corporation的董事会成员和薪酬委员会负责人，以及初创眼科公司reVision Therapeutics的顾问。Gregory女士目前是Rgenta Therapeutics的业务发展主管，Rgenta Therapeutics是一家小分子RNA调制公司。此前，她担任战略咨询公司KG BioPharma Consulting LLC的总裁，协助中小型生物制药公司开展一系列公司战略和业务发展活动。在加入KG BioPharma之前，她是Antengene Corporation的副总裁兼业务发展全球主管，该公司是一家专注于亚太地区患者创新药物的血液学和肿瘤学公司。在加入Antengene之前，Gregory女士是总部位于波士顿的肿瘤学公司Aileron Therapeutics的首席商务官。在她职业生涯的早期，Gregory女士是Seneb BioSciences的联合创始人兼首席执行官，这是一家早期的罕见病公司，被一家中型生物技术公司收购。Gregory女士还曾在Purdue Pharma和Shire Pharmaceuticals担任高级职务。Gregory女士获得了佩珀代因大学的工商管理硕士学位和加州大学伯克利分校的学士学位。
Kathryn Gregory has over 25 years of executive leadership experience in startup, mid sized and large pharmaceutical and biotechnology companies. She has extensive experience in international business development including corporate strategy, licensing, mergers and acquisitions and alliance management. Ms. Gregory joined the Board of Directors of the Company in February 2024 and is Chair of the Human Resources Committee. She also is on the board of directors and Head of Compensation Committee of Carmell Corporation, an aesthetics company, and an advisor to reVision Therapeutics, a startup ophthalmology company. Ms. Gregory is currently Head of Business Development at Rgenta Therapeutics, a small molecule RNA modulation company. Previously, she was President of KG BioPharma Consulting LLC, a strategic advisory company, where she assisted small and mid size biopharma companies in a range of corporate strategy and business development activities. Prior to KG BioPharma, she was Vice President and Global Head of Business Development for Antengene Corporation, a hematology and oncology company focused on innovative medicines for patients in the Asia Pacific Region. Prior to Antengene, Ms. Gregory was Chief Business Officer of Aileron Therapeutics, a Boston based oncology company. Earlier in her career, Ms. Gregory was Co Founder and CEO for Seneb BioSciences, an early stage, rare disease company which was acquired by a mid sized biotech firm. Ms. Gregory also worked in senior roles at Purdue Pharma and Shire Pharmaceuticals. Ms. Gregory received an M.B.A. from Pepperdine University and a B.A. degree from the University of California, Berkeley. - Kathryn Gregory在初创、中型和大型制药和生物技术公司拥有超过25年的执行领导经验。她在国际业务发展方面拥有丰富的经验，包括公司战略、许可、并购和联盟管理。Gregory女士于2024年2月加入公司董事会，并担任人力资源委员会主席。她也是美容公司Carmell Corporation的董事会成员和薪酬委员会负责人，以及初创眼科公司reVision Therapeutics的顾问。Gregory女士目前是Rgenta Therapeutics的业务发展主管，Rgenta Therapeutics是一家小分子RNA调制公司。此前，她担任战略咨询公司KG BioPharma Consulting LLC的总裁，协助中小型生物制药公司开展一系列公司战略和业务发展活动。在加入KG BioPharma之前，她是Antengene Corporation的副总裁兼业务发展全球主管，该公司是一家专注于亚太地区患者创新药物的血液学和肿瘤学公司。在加入Antengene之前，Gregory女士是总部位于波士顿的肿瘤学公司Aileron Therapeutics的首席商务官。在她职业生涯的早期，Gregory女士是Seneb BioSciences的联合创始人兼首席执行官，这是一家早期的罕见病公司，被一家中型生物技术公司收购。Gregory女士还曾在Purdue Pharma和Shire Pharmaceuticals担任高级职务。Gregory女士获得了佩珀代因大学的工商管理硕士学位和加州大学伯克利分校的学士学位。
- Kathryn Gregory has over 25 years of executive leadership experience in startup, mid sized and large pharmaceutical and biotechnology companies. She has extensive experience in international business development including corporate strategy, licensing, mergers and acquisitions and alliance management. Ms. Gregory joined the Board of Directors of the Company in February 2024 and is Chair of the Human Resources Committee. She also is on the board of directors and Head of Compensation Committee of Carmell Corporation, an aesthetics company, and an advisor to reVision Therapeutics, a startup ophthalmology company. Ms. Gregory is currently Head of Business Development at Rgenta Therapeutics, a small molecule RNA modulation company. Previously, she was President of KG BioPharma Consulting LLC, a strategic advisory company, where she assisted small and mid size biopharma companies in a range of corporate strategy and business development activities. Prior to KG BioPharma, she was Vice President and Global Head of Business Development for Antengene Corporation, a hematology and oncology company focused on innovative medicines for patients in the Asia Pacific Region. Prior to Antengene, Ms. Gregory was Chief Business Officer of Aileron Therapeutics, a Boston based oncology company. Earlier in her career, Ms. Gregory was Co Founder and CEO for Seneb BioSciences, an early stage, rare disease company which was acquired by a mid sized biotech firm. Ms. Gregory also worked in senior roles at Purdue Pharma and Shire Pharmaceuticals. Ms. Gregory received an M.B.A. from Pepperdine University and a B.A. degree from the University of California, Berkeley.
- Luc Grégoire
-
Luc Gr é goire是一位经验丰富的战略主管，在软件、数字媒体和娱乐以及健康科学等多个行业拥有丰富的经验。他在安达信开始了他的职业生涯，在那里他是一名国际税务合伙人。随后，他在默沙东公司担任过多个财务和战略职务，包括默沙东 Frost Canada的首席财务官，并在默沙东的美国公司总部晋升为全球高级职位。Gr é goire先生最近担任Informed Data Services Inc（d/b/a One Drop）（“InfoMed”）的首席财务官，该公司是一家处于增长阶段的糖尿病管理健康技术和医疗设备公司，由拜耳提供支持。自2022年10月1日起，Gr é goire先生从InfoMed首席财务官的职位上退休。在加入InfoMed之前，Gr é goire先生于2016年11月至2021年1月担任戴斯控股集团有限公司（DHX，NYSE）的首席财务官，并于2014年10月至2016年10月担任AvePoint Inc.（AVPT，NYSE）的首席财务官。在加入AvePoint公司之前，Gr é goire先生曾在这些全球上市公司担任不同的执行财务职务：以两家Interactive Inc，即麦格劳希尔公司和Standard Motor产品公司为例。他的职业生涯跨越40年，在会计、税务、财务、财务规划、审计、并购、资本市场和投资者关系、公司治理以及国际运营和一般商业管理方面拥有丰富的经验。在他的职业生涯中，他培养了有效和战略性的领导技能以及广泛的公共和私人资本市场外联战略，包括与投资者的持续互动、买卖方分析师、资本筹集和股东积极主义。自2016年以来，Gr é goire先生还担任总部位于纽约的住宅房地产公司Werber Management Inc.的董事会成员。Gr é goire先生是注册会计师，同时毕业于Concordia University — B. Comm（1981）和McGill University — Graduate Dipl。会计。
Luc Grégoire is a seasoned strategic executive, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global senior roles in Merck's US corporate headquarters. Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) ("InfoMed"), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Grégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and CFO of AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc. His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisitions, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell side analysts, capital raises and shareholder activism. Since 2016, Mr. Grégoire has also served on the board of directors of Werber Management Inc., a New York based residential real estate company. Mr. Grégoire is a CPA Chartered Accountant, as well as a graduate of Concordia University — B. Comm (1981) and McGill University—Graduate Dipl. Accountancy. - Luc Gr é goire是一位经验丰富的战略主管，在软件、数字媒体和娱乐以及健康科学等多个行业拥有丰富的经验。他在安达信开始了他的职业生涯，在那里他是一名国际税务合伙人。随后，他在默沙东公司担任过多个财务和战略职务，包括默沙东 Frost Canada的首席财务官，并在默沙东的美国公司总部晋升为全球高级职位。Gr é goire先生最近担任Informed Data Services Inc（d/b/a One Drop）（“InfoMed”）的首席财务官，该公司是一家处于增长阶段的糖尿病管理健康技术和医疗设备公司，由拜耳提供支持。自2022年10月1日起，Gr é goire先生从InfoMed首席财务官的职位上退休。在加入InfoMed之前，Gr é goire先生于2016年11月至2021年1月担任戴斯控股集团有限公司（DHX，NYSE）的首席财务官，并于2014年10月至2016年10月担任AvePoint Inc.（AVPT，NYSE）的首席财务官。在加入AvePoint公司之前，Gr é goire先生曾在这些全球上市公司担任不同的执行财务职务：以两家Interactive Inc，即麦格劳希尔公司和Standard Motor产品公司为例。他的职业生涯跨越40年，在会计、税务、财务、财务规划、审计、并购、资本市场和投资者关系、公司治理以及国际运营和一般商业管理方面拥有丰富的经验。在他的职业生涯中，他培养了有效和战略性的领导技能以及广泛的公共和私人资本市场外联战略，包括与投资者的持续互动、买卖方分析师、资本筹集和股东积极主义。自2016年以来，Gr é goire先生还担任总部位于纽约的住宅房地产公司Werber Management Inc.的董事会成员。Gr é goire先生是注册会计师，同时毕业于Concordia University — B. Comm（1981）和McGill University — Graduate Dipl。会计。
- Luc Grégoire is a seasoned strategic executive, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global senior roles in Merck's US corporate headquarters. Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) ("InfoMed"), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Grégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and CFO of AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc. His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisitions, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell side analysts, capital raises and shareholder activism. Since 2016, Mr. Grégoire has also served on the board of directors of Werber Management Inc., a New York based residential real estate company. Mr. Grégoire is a CPA Chartered Accountant, as well as a graduate of Concordia University — B. Comm (1981) and McGill University—Graduate Dipl. Accountancy.
- Louis Flamand
-
Louis Flamand是魁北克省拉瓦尔大学医学院微生物学、传染病和免疫学系的正教授和系主任，也是CHU de Qu é bec研究中心传染病和免疫疾病分部的高级研究员。在加入拉瓦尔大学之前，Flamand博士在蒙特利尔大学获得博士学位，并在美国国立卫生研究院和人类病毒学研究所（美国马里兰州）获得博士后培训。他在拉瓦尔大学获得了医药管理MBA学位。2008年至2019年，他担任拉瓦尔大学生物危害风险委员会主席。自2006年以来，他还是HHV 6基金会科学顾问委员会的成员。Flamand博士具有临床前开发经验。在他的整个职业生涯中，Flamand博士因其在病毒学方面的工作而获得了多个竞争性奖学金奖项和来自多个资助机构的持续资助支持。Flamand博士是100多篇同行评审出版物的作者，并且是《人类疱疹病毒HHV 6A、HHV 6B和HHV 7：诊断和临床管理》一书第3版的主编。
Louis Flamand is a full professor and Chair of the department of microbiology, infectious disease and immunology at the faculty of medicine, Université Laval, Québec and senior researcher in the division of infectious and immune diseases at the CHU de Québec research center. Before joining Université Laval, Dr. Flamand obtained his PhD at the Université de Montréal and post doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, United States). He received his MBA in pharmaceutical management from Université Laval. From 2008 to 2019, he was President of the biohazard's risks committee at Université Laval. He is also member of the HHV 6 Foundation scientific advisory board since 2006. Dr. Flamand has experience in pre clinical development. Throughout his career, Dr. Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr. Flamand is the author of more than 100 peer reviewed publications and is lead Editor of the book "Human Herpesviruses HHV 6A, HHV 6B & HHV 7: Diagnosis and Clinical Management" 3rd Edition. - Louis Flamand是魁北克省拉瓦尔大学医学院微生物学、传染病和免疫学系的正教授和系主任，也是CHU de Qu é bec研究中心传染病和免疫疾病分部的高级研究员。在加入拉瓦尔大学之前，Flamand博士在蒙特利尔大学获得博士学位，并在美国国立卫生研究院和人类病毒学研究所（美国马里兰州）获得博士后培训。他在拉瓦尔大学获得了医药管理MBA学位。2008年至2019年，他担任拉瓦尔大学生物危害风险委员会主席。自2006年以来，他还是HHV 6基金会科学顾问委员会的成员。Flamand博士具有临床前开发经验。在他的整个职业生涯中，Flamand博士因其在病毒学方面的工作而获得了多个竞争性奖学金奖项和来自多个资助机构的持续资助支持。Flamand博士是100多篇同行评审出版物的作者，并且是《人类疱疹病毒HHV 6A、HHV 6B和HHV 7：诊断和临床管理》一书第3版的主编。
- Louis Flamand is a full professor and Chair of the department of microbiology, infectious disease and immunology at the faculty of medicine, Université Laval, Québec and senior researcher in the division of infectious and immune diseases at the CHU de Québec research center. Before joining Université Laval, Dr. Flamand obtained his PhD at the Université de Montréal and post doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, United States). He received his MBA in pharmaceutical management from Université Laval. From 2008 to 2019, he was President of the biohazard's risks committee at Université Laval. He is also member of the HHV 6 Foundation scientific advisory board since 2006. Dr. Flamand has experience in pre clinical development. Throughout his career, Dr. Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr. Flamand is the author of more than 100 peer reviewed publications and is lead Editor of the book "Human Herpesviruses HHV 6A, HHV 6B & HHV 7: Diagnosis and Clinical Management" 3rd Edition.
- Luc Buisson
-
Luc Buisson是一名高级战略和财务顾问主管，在全球投资银行、企业融资和复杂的跨境交易方面拥有超过35年的经验。他此前曾在加拿大和整个美洲的汇丰银行担任副主席，他在为政府、企业、养老基金和机构投资者就具有里程碑意义的并购、资本市场和总价值超过200B美元的战略金融交易提供咨询方面有着卓越的业绩记录。Buisson先生因其稳健的判断力、谨慎的判断力以及驾驭复杂的利益相关者环境的能力而受到认可。他凭借在并购、资本结构优化、交易执行方面的深厚专业知识，结合协同领导和强有力的治理导向，为董事会、CEO和高级管理人员提供清晰、务实的建议。
Luc Buisson is a senior strategic and financial advisory executive with more than 35 years of experience in global investment banking, corporate finance, and complex cross border transactions. He previously served as Vice Chair at HSBC in Canada and across the Americas, and he has a distinguished track record advising governments, corporations, pension funds, and institutional investors on landmark M&A, capital markets, and strategic finance transactions exceeding $200B in aggregate value. Mr. Buisson is recognized for sound judgment, discretion, and the ability to navigate complex stakeholder environments. He provides clear, pragmatic advice to boards, CEOs, and senior executives drawing on deep expertise in mergers and acquisitions, capital structure optimization, and transaction execution, combined with collaborative leadership and strong governance orientation. - Luc Buisson是一名高级战略和财务顾问主管，在全球投资银行、企业融资和复杂的跨境交易方面拥有超过35年的经验。他此前曾在加拿大和整个美洲的汇丰银行担任副主席，他在为政府、企业、养老基金和机构投资者就具有里程碑意义的并购、资本市场和总价值超过200B美元的战略金融交易提供咨询方面有着卓越的业绩记录。Buisson先生因其稳健的判断力、谨慎的判断力以及驾驭复杂的利益相关者环境的能力而受到认可。他凭借在并购、资本结构优化、交易执行方面的深厚专业知识，结合协同领导和强有力的治理导向，为董事会、CEO和高级管理人员提供清晰、务实的建议。
- Luc Buisson is a senior strategic and financial advisory executive with more than 35 years of experience in global investment banking, corporate finance, and complex cross border transactions. He previously served as Vice Chair at HSBC in Canada and across the Americas, and he has a distinguished track record advising governments, corporations, pension funds, and institutional investors on landmark M&A, capital markets, and strategic finance transactions exceeding $200B in aggregate value. Mr. Buisson is recognized for sound judgment, discretion, and the ability to navigate complex stakeholder environments. He provides clear, pragmatic advice to boards, CEOs, and senior executives drawing on deep expertise in mergers and acquisitions, capital structure optimization, and transaction execution, combined with collaborative leadership and strong governance orientation.
- Dennis Turpin
-
Dennis Turpin，2007年8月，被任命本公司高级副总裁兼首席财务总监。在此之前，自1999年6月起，他曾担任本公司副总裁兼首席财务官。他于1996年8月加入 Aeterna Zentaris ，担任财务总监。此前，1988-1996，他担任Coopers Lybrand（现普华永道）税务部门总监，1985-1988，担任审计师。他获得了魁北克拉瓦尔大学的会计学士学位，于1985年他获得了会计从业许可证，1987年成为特许会计师。
Dennis Turpin was appointed Senior Vice President and Chief Financial Officer in August 2007. Prior to that, he served as Vice President and Chief Financial Officer since June 1999. Mr. Turpin joined Aeterna Zentaris in August 1996 as Director of Finance. Prior to that, he was Director in the tax department at Coopers Lybrand, now PricewaterhouseCoopers, from 1988 to 1996 and worked as an auditor from 1985 to 1988. Mr. Turpin earned his Bachelor's degree in Accounting from Laval University in Québec. He obtained his license in accounting in 1985 and became a chartered accountant in 1987. - Dennis Turpin，2007年8月，被任命本公司高级副总裁兼首席财务总监。在此之前，自1999年6月起，他曾担任本公司副总裁兼首席财务官。他于1996年8月加入 Aeterna Zentaris ，担任财务总监。此前，1988-1996，他担任Coopers Lybrand（现普华永道）税务部门总监，1985-1988，担任审计师。他获得了魁北克拉瓦尔大学的会计学士学位，于1985年他获得了会计从业许可证，1987年成为特许会计师。
- Dennis Turpin was appointed Senior Vice President and Chief Financial Officer in August 2007. Prior to that, he served as Vice President and Chief Financial Officer since June 1999. Mr. Turpin joined Aeterna Zentaris in August 1996 as Director of Finance. Prior to that, he was Director in the tax department at Coopers Lybrand, now PricewaterhouseCoopers, from 1988 to 1996 and worked as an auditor from 1985 to 1988. Mr. Turpin earned his Bachelor's degree in Accounting from Laval University in Québec. He obtained his license in accounting in 1985 and became a chartered accountant in 1987.
高管简历
中英对照 | 中文 | 英文- André P. Boulet
Andr é P. Boulet在制药和生物技术领域的药物开发、监管事务、市场准入、融资和重组方面拥有丰富的经验。2025年6月，他被任命为首席执行官兼首席科学官（“CSO”）。2022年8月，Boulet博士被任命为公司CSO。2015年3月至2022年8月，Boulet博士担任公司总裁兼首席执行官，并购买了PurGenesis Technologies Inc.（“PurGenesis”）的资产，该公司是一家专门开发植物药物以及皮肤美容产品的公司。此外，他在2013年7月至2015年2月期间担任顾问。他与美国一家大型有机农场建立了战略合作伙伴关系，以供应用于提取PurGenesis旗舰产品的原材料。在他的领导下，还建造了一座药物提取设施。在加入PurGenesis之前，Boulet博士是SIPAR BIO Inc.的合伙人兼科学事务副总裁，该公司是一家私募股权团队，也是加拿大生物技术公司BioCapital Investment Limited Partnership和BioCapital Mutual Fund（19962002）的合伙人，负责投资战略、交易发展分析、估值以及对私营和上市公司的选定投资的谈判。Boulet博士还在2000年11月至2008年12月期间担任Bioxel Pharma Inc.的董事和高级管理人员。在其整个职业生涯中，Boulet博士与Hoechst Marion Roussel Inc.、Marion Merrell Dow Canada Inc.和Nordic Laboratories Inc.（现为赛诺菲 Canada Inc.）合作，发展了药物开发和健康经济学方面的国际专业知识。Boulet博士自1981年9月起拥有魁北克河畔三河大学医学生物学学士学位，并于1985年6月获得实验医学/免疫学免疫化学硕士学位，于1988年6月获得魁北克市拉瓦尔大学生理内分泌学博士学位。他还在美国宾夕法尼亚大学完成了生物化学和生物物理学博士后研究金，并在英国约克大学完成了卫生经济学培训项目。他因基础研究连续两年获得Ortho Pharmaceutical奖，分别于1986年和1987年；获得Fonds de Recherche du Qu é bec — Sant é的研究生奖学金（19871988）和博士后培训（19881990）。他于1993年成为美国高血压学会的教员，并于1994年至1996年在FDA心肺CRADA指导委员会任职，评估动态血压监测数据在批准新型抗高血压药物方面的潜在用途。他是多篇与基础和临床研究、金融和卫生经济学相关的手稿的作者或合著者。他是三项专利的共同作者。
André P. Boulet has vast experience in drug development, regulatory affairs, market access, financing and restructuring in the pharmaceutical and biotech fields. In June 2025, he was appointed as CEO and Chief Scientific Officer ("CSO"). In August 2022, Dr. Boulet was appointed as CSO of the Company. From March 2015 to August 2022, Dr. Boulet was President and CEO of the Company and purchased the assets of PurGenesis Technologies Inc., ("PurGenesis") a corporation specialized in the development of botanical drugs as well as derma cosmetic products. Also, he was a consultant from July 2013 to February 2015. He established a strategic partnership with a large United States based organic farm to supply the raw material used for the extraction of PurGenesis' flagship product. A pharmaceutical extraction facility was also built under his leadership. Prior to joining PurGenesis, Dr. Boulet was partner and Vice President Scientific affairs of SIPAR BIO Inc., a private equity team and a partner in BioCapital Investment Limited Partnership and BioCapital Mutual Fund (1996 2002), a Canadian biotechnology corporation, where he was responsible for investment strategy, deal development analysis, valuation, and negotiation of selected investments in private and publicly traded corporations. Dr. Boulet has also been a Director and Senior Officer of Bioxel Pharma Inc. from November 2000 to December 2008. Throughout his career, Dr. Boulet developed international expertise in the drug development and health economics, working with Hoechst Marion Roussel Inc., Marion Merrell Dow Canada Inc. and Nordic Laboratories Inc. (now Sanofi Canada Inc.). Dr. Boulet holds a bachelor's degree in medical biology from Université du Québec à Trois Rivières since September 1981, a master's degree in experimental medicine/immunology immunochemistry as well in June 1985 and a Ph.D. in physiology endocrinology in June 1988 from Université Laval in Québec City. He also completed a postdoctoral fellowship in biochemistry and biophysics at the University of Pennsylvania, in the United States, and a training program in health economics at York University, in the United Kingdom. He received the Ortho Pharmaceutical award for basic research, on two consecutive years, in 1986 and 1987; received Graduate Student Fellowship (1987 1988) and Postdoctoral training (1988 1990) both from the Fonds de Recherche du Québec—Santé. He was Faculty member of the American Society of Hypertension, Inc. in 1993 and served on the FDA Cardio Renal CRADA Steering Committee from 1994 to 1996, assessing the potential use of ambulatory blood pressure monitoring data for the approval of new anti hypertensive drugs. He is the author or co author of many manuscripts related to basic and clinical research, finance and health economics. He is the co author of three patents.- Andr é P. Boulet在制药和生物技术领域的药物开发、监管事务、市场准入、融资和重组方面拥有丰富的经验。2025年6月，他被任命为首席执行官兼首席科学官（“CSO”）。2022年8月，Boulet博士被任命为公司CSO。2015年3月至2022年8月，Boulet博士担任公司总裁兼首席执行官，并购买了PurGenesis Technologies Inc.（“PurGenesis”）的资产，该公司是一家专门开发植物药物以及皮肤美容产品的公司。此外，他在2013年7月至2015年2月期间担任顾问。他与美国一家大型有机农场建立了战略合作伙伴关系，以供应用于提取PurGenesis旗舰产品的原材料。在他的领导下，还建造了一座药物提取设施。在加入PurGenesis之前，Boulet博士是SIPAR BIO Inc.的合伙人兼科学事务副总裁，该公司是一家私募股权团队，也是加拿大生物技术公司BioCapital Investment Limited Partnership和BioCapital Mutual Fund（19962002）的合伙人，负责投资战略、交易发展分析、估值以及对私营和上市公司的选定投资的谈判。Boulet博士还在2000年11月至2008年12月期间担任Bioxel Pharma Inc.的董事和高级管理人员。在其整个职业生涯中，Boulet博士与Hoechst Marion Roussel Inc.、Marion Merrell Dow Canada Inc.和Nordic Laboratories Inc.（现为赛诺菲 Canada Inc.）合作，发展了药物开发和健康经济学方面的国际专业知识。Boulet博士自1981年9月起拥有魁北克河畔三河大学医学生物学学士学位，并于1985年6月获得实验医学/免疫学免疫化学硕士学位，于1988年6月获得魁北克市拉瓦尔大学生理内分泌学博士学位。他还在美国宾夕法尼亚大学完成了生物化学和生物物理学博士后研究金，并在英国约克大学完成了卫生经济学培训项目。他因基础研究连续两年获得Ortho Pharmaceutical奖，分别于1986年和1987年；获得Fonds de Recherche du Qu é bec — Sant é的研究生奖学金（19871988）和博士后培训（19881990）。他于1993年成为美国高血压学会的教员，并于1994年至1996年在FDA心肺CRADA指导委员会任职，评估动态血压监测数据在批准新型抗高血压药物方面的潜在用途。他是多篇与基础和临床研究、金融和卫生经济学相关的手稿的作者或合著者。他是三项专利的共同作者。
- André P. Boulet has vast experience in drug development, regulatory affairs, market access, financing and restructuring in the pharmaceutical and biotech fields. In June 2025, he was appointed as CEO and Chief Scientific Officer ("CSO"). In August 2022, Dr. Boulet was appointed as CSO of the Company. From March 2015 to August 2022, Dr. Boulet was President and CEO of the Company and purchased the assets of PurGenesis Technologies Inc., ("PurGenesis") a corporation specialized in the development of botanical drugs as well as derma cosmetic products. Also, he was a consultant from July 2013 to February 2015. He established a strategic partnership with a large United States based organic farm to supply the raw material used for the extraction of PurGenesis' flagship product. A pharmaceutical extraction facility was also built under his leadership. Prior to joining PurGenesis, Dr. Boulet was partner and Vice President Scientific affairs of SIPAR BIO Inc., a private equity team and a partner in BioCapital Investment Limited Partnership and BioCapital Mutual Fund (1996 2002), a Canadian biotechnology corporation, where he was responsible for investment strategy, deal development analysis, valuation, and negotiation of selected investments in private and publicly traded corporations. Dr. Boulet has also been a Director and Senior Officer of Bioxel Pharma Inc. from November 2000 to December 2008. Throughout his career, Dr. Boulet developed international expertise in the drug development and health economics, working with Hoechst Marion Roussel Inc., Marion Merrell Dow Canada Inc. and Nordic Laboratories Inc. (now Sanofi Canada Inc.). Dr. Boulet holds a bachelor's degree in medical biology from Université du Québec à Trois Rivières since September 1981, a master's degree in experimental medicine/immunology immunochemistry as well in June 1985 and a Ph.D. in physiology endocrinology in June 1988 from Université Laval in Québec City. He also completed a postdoctoral fellowship in biochemistry and biophysics at the University of Pennsylvania, in the United States, and a training program in health economics at York University, in the United Kingdom. He received the Ortho Pharmaceutical award for basic research, on two consecutive years, in 1986 and 1987; received Graduate Student Fellowship (1987 1988) and Postdoctoral training (1988 1990) both from the Fonds de Recherche du Québec—Santé. He was Faculty member of the American Society of Hypertension, Inc. in 1993 and served on the FDA Cardio Renal CRADA Steering Committee from 1994 to 1996, assessing the potential use of ambulatory blood pressure monitoring data for the approval of new anti hypertensive drugs. He is the author or co author of many manuscripts related to basic and clinical research, finance and health economics. He is the co author of three patents.
- Luc Grégoire
Luc Gr é goire是一位经验丰富的战略主管，在软件、数字媒体和娱乐以及健康科学等多个行业拥有丰富的经验。他在安达信开始了他的职业生涯，在那里他是一名国际税务合伙人。随后，他在默沙东公司担任过多个财务和战略职务，包括默沙东 Frost Canada的首席财务官，并在默沙东的美国公司总部晋升为全球高级职位。Gr é goire先生最近担任Informed Data Services Inc（d/b/a One Drop）（“InfoMed”）的首席财务官，该公司是一家处于增长阶段的糖尿病管理健康技术和医疗设备公司，由拜耳提供支持。自2022年10月1日起，Gr é goire先生从InfoMed首席财务官的职位上退休。在加入InfoMed之前，Gr é goire先生于2016年11月至2021年1月担任戴斯控股集团有限公司（DHX，NYSE）的首席财务官，并于2014年10月至2016年10月担任AvePoint Inc.（AVPT，NYSE）的首席财务官。在加入AvePoint公司之前，Gr é goire先生曾在这些全球上市公司担任不同的执行财务职务：以两家Interactive Inc，即麦格劳希尔公司和Standard Motor产品公司为例。他的职业生涯跨越40年，在会计、税务、财务、财务规划、审计、并购、资本市场和投资者关系、公司治理以及国际运营和一般商业管理方面拥有丰富的经验。在他的职业生涯中，他培养了有效和战略性的领导技能以及广泛的公共和私人资本市场外联战略，包括与投资者的持续互动、买卖方分析师、资本筹集和股东积极主义。自2016年以来，Gr é goire先生还担任总部位于纽约的住宅房地产公司Werber Management Inc.的董事会成员。Gr é goire先生是注册会计师，同时毕业于Concordia University — B. Comm（1981）和McGill University — Graduate Dipl。会计。
Luc Grégoire is a seasoned strategic executive, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global senior roles in Merck's US corporate headquarters. Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) ("InfoMed"), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Grégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and CFO of AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc. His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisitions, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell side analysts, capital raises and shareholder activism. Since 2016, Mr. Grégoire has also served on the board of directors of Werber Management Inc., a New York based residential real estate company. Mr. Grégoire is a CPA Chartered Accountant, as well as a graduate of Concordia University — B. Comm (1981) and McGill University—Graduate Dipl. Accountancy.- Luc Gr é goire是一位经验丰富的战略主管，在软件、数字媒体和娱乐以及健康科学等多个行业拥有丰富的经验。他在安达信开始了他的职业生涯，在那里他是一名国际税务合伙人。随后，他在默沙东公司担任过多个财务和战略职务，包括默沙东 Frost Canada的首席财务官，并在默沙东的美国公司总部晋升为全球高级职位。Gr é goire先生最近担任Informed Data Services Inc（d/b/a One Drop）（“InfoMed”）的首席财务官，该公司是一家处于增长阶段的糖尿病管理健康技术和医疗设备公司，由拜耳提供支持。自2022年10月1日起，Gr é goire先生从InfoMed首席财务官的职位上退休。在加入InfoMed之前，Gr é goire先生于2016年11月至2021年1月担任戴斯控股集团有限公司（DHX，NYSE）的首席财务官，并于2014年10月至2016年10月担任AvePoint Inc.（AVPT，NYSE）的首席财务官。在加入AvePoint公司之前，Gr é goire先生曾在这些全球上市公司担任不同的执行财务职务：以两家Interactive Inc，即麦格劳希尔公司和Standard Motor产品公司为例。他的职业生涯跨越40年，在会计、税务、财务、财务规划、审计、并购、资本市场和投资者关系、公司治理以及国际运营和一般商业管理方面拥有丰富的经验。在他的职业生涯中，他培养了有效和战略性的领导技能以及广泛的公共和私人资本市场外联战略，包括与投资者的持续互动、买卖方分析师、资本筹集和股东积极主义。自2016年以来，Gr é goire先生还担任总部位于纽约的住宅房地产公司Werber Management Inc.的董事会成员。Gr é goire先生是注册会计师，同时毕业于Concordia University — B. Comm（1981）和McGill University — Graduate Dipl。会计。
- Luc Grégoire is a seasoned strategic executive, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global senior roles in Merck's US corporate headquarters. Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) ("InfoMed"), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Grégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and CFO of AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc. His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisitions, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell side analysts, capital raises and shareholder activism. Since 2016, Mr. Grégoire has also served on the board of directors of Werber Management Inc., a New York based residential real estate company. Mr. Grégoire is a CPA Chartered Accountant, as well as a graduate of Concordia University — B. Comm (1981) and McGill University—Graduate Dipl. Accountancy.
- Dennis Turpin
Dennis Turpin，2007年8月，被任命本公司高级副总裁兼首席财务总监。在此之前，自1999年6月起，他曾担任本公司副总裁兼首席财务官。他于1996年8月加入 Aeterna Zentaris ，担任财务总监。此前，1988-1996，他担任Coopers Lybrand（现普华永道）税务部门总监，1985-1988，担任审计师。他获得了魁北克拉瓦尔大学的会计学士学位，于1985年他获得了会计从业许可证，1987年成为特许会计师。
Dennis Turpin was appointed Senior Vice President and Chief Financial Officer in August 2007. Prior to that, he served as Vice President and Chief Financial Officer since June 1999. Mr. Turpin joined Aeterna Zentaris in August 1996 as Director of Finance. Prior to that, he was Director in the tax department at Coopers Lybrand, now PricewaterhouseCoopers, from 1988 to 1996 and worked as an auditor from 1985 to 1988. Mr. Turpin earned his Bachelor's degree in Accounting from Laval University in Québec. He obtained his license in accounting in 1985 and became a chartered accountant in 1987.- Dennis Turpin，2007年8月，被任命本公司高级副总裁兼首席财务总监。在此之前，自1999年6月起，他曾担任本公司副总裁兼首席财务官。他于1996年8月加入 Aeterna Zentaris ，担任财务总监。此前，1988-1996，他担任Coopers Lybrand（现普华永道）税务部门总监，1985-1988，担任审计师。他获得了魁北克拉瓦尔大学的会计学士学位，于1985年他获得了会计从业许可证，1987年成为特许会计师。
- Dennis Turpin was appointed Senior Vice President and Chief Financial Officer in August 2007. Prior to that, he served as Vice President and Chief Financial Officer since June 1999. Mr. Turpin joined Aeterna Zentaris in August 1996 as Director of Finance. Prior to that, he was Director in the tax department at Coopers Lybrand, now PricewaterhouseCoopers, from 1988 to 1996 and worked as an auditor from 1985 to 1988. Mr. Turpin earned his Bachelor's degree in Accounting from Laval University in Québec. He obtained his license in accounting in 1985 and became a chartered accountant in 1987.